NCT01456039 - A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 1, 2011

Primary Completion Date

July 28, 2015

Study Completion Date

December 14, 2018

Conditions

Lymphoma, T-cell, Peripheral

Interventions

DRUG

Romidepsin

Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle

Trial Locations (17)

466-8650

Nagoya Daini Red Cross Hospital, Nagoya

467-8602

Nagoya City University Hospital, Nagoya

277-8577:

National Cancer Center Hospital East, Kashiwa

791-0295

Ehime University Hospital, Tōon

720-0001

Chugoku Central Hospital, Fukuyamashi

003-0006

Sapporo Hokuyu Hospital, Sapporo

060-8543

Sapporo Medical University Hospital, Sapporo

259-1193

Tokai University School of Medicine, Isehara

783-8505

Kochi Medical School Hospital, Nankoku

589-8511

Kinki University Hospital, Sayama

104-0045

National Cancer Center Hospital, Chūō

150-8935

Japanese Red Cross Medical Center, Shibuya City

812-8582

Kyushu University Hospital, Fukuoka

860-8556

Kumamoto University Hospital, Kumamoto

602-8566

University hospital, Kyoto prefectural University of Medicine, Kyoto

980-8574

Tohoku University Hospital, Miyagi

135-8550

The Cancer Institute Hospital of JFCR, Tokyo